

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE MEDICINAL PRODUCT

ZINPLAVA 25 mg/mL concentrate for solution for infusion

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each mL of concentrate contains 25 mg bezlotoxumab.

One 40 mL vial contains 1 000 mg of bezlotoxumab.

One 25 mL vial contains 625 mg of bezlotoxumab.

Bezlotoxumab is a human monoclonal antibody produced in Chinese hamster ovary cells by recombinant DNA technology. It binds to *C. difficile* toxin B.

### Excipient with known effect

Each mL of concentrate contains 0.2 mmol sodium, which is 4.57 mg sodium.

This corresponds to 182.8 mg of sodium per vial (for the 40 mL vial presentation) or 114.3 mg of sodium per vial (for the 25 mL vial presentation).

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Concentrate for solution for infusion.

Clear to moderately opalescent, colourless to pale yellow liquid.

## 4. CLINICAL PARTICULARS

### 4.1 Therapeutic indications

ZINPLAVA is indicated for the prevention of recurrence of *Clostridioides difficile* infection (CDI) in adult and paediatric patients 1 year of age and older at high risk for recurrence of CDI (see sections 4.2, 4.4 and 5.1).

### 4.2 Posology and method of administration

#### Posology

ZINPLAVA should be administered during the course of antibacterial therapy for CDI (see sections 4.4 and 5.1).

#### *Adult and paediatric patients 1 year of age and older*

ZINPLAVA should be administered as a single intravenous infusion of 10 mg/kg (see below and section 6.6).

The experience with ZINPLAVA in patients is limited to a single CDI episode and single administration (see section 4.4).

#### Special populations

##### *Elderly*

No dose adjustment is necessary in patients  $\geq 65$  years of age (see section 5.2).

#### *Renal impairment*

No dose adjustment is necessary for patients with renal impairment (see section 5.2).

#### *Hepatic impairment*

No dose adjustment is necessary for patients with hepatic impairment (see section 5.2).

#### *Paediatric population*

There is no relevant use of bezlotoxumab in children under 1 year of age for the indication of prevention of CDI.

#### Method of administration

- Administer the diluted solution for infusion intravenously over 60 minutes using a sterile, non-pyrogenic, low-protein binding 0.2 micron to 5 micron in-line or add-on filter. ZINPLAVA should not be administered as an intravenous push or bolus.
- The diluted solution can be infused via a central line or peripheral catheter.
- ZINPLAVA must not be co-administered with other medicinal products simultaneously through the same infusion line.

For instructions on dilution of the medicinal product before administration, see section 6.6.

### **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

### **4.4 Special warnings and precautions for use**

#### Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

ZINPLAVA is not a treatment for CDI and has no effect on the current CDI episode. ZINPLAVA should be administered during the course of antibacterial therapy for CDI. There is no data regarding the efficacy of ZINPLAVA if given after the initial 10- to 14-days of antibacterial therapy for CDI.

ZINPLAVA should not be administered as an intravenous push or bolus.

There is no experience with repeat administration of ZINPLAVA in patients with CDI. In clinical trials, patients with CDI were only administered a single dose of ZINPLAVA (see section 5.1).

#### Sodium

This medicinal product contains up to 182.8 mg sodium per vial, equivalent to 9.1 % of the WHO recommended maximum daily intake of 2 g sodium for an adult.

### **4.5 Interaction with other medicinal products and other forms of interaction**

No formal interactions studies with other medicinal products were conducted. Therapeutic monoclonal antibodies do not typically have significant drug-drug interaction potential, as they do not directly affect cytochrome P450 enzymes and are not substrates of hepatic or renal transporters.

Bezlotoxumab-mediated drug-drug interactions are unlikely as the target of bezlotoxumab is an exogenous toxin.

Concomitant oral standard of care (SoC) antibacterial therapy for CDI was given together with ZINPLAVA.

## 4.6 Fertility, pregnancy and lactation

### Pregnancy

There are limited data from the use of bezlotoxumab in pregnant women. Animal studies do not indicate reproductive toxicity (see section 5.3). ZINPLAVA should not be used during pregnancy unless the clinical condition of the woman requires treatment with bezlotoxumab.

### Breast-feeding

It is unknown whether bezlotoxumab is secreted in human milk. Because monoclonal antibodies may be excreted in human milk, a decision should be made whether to discontinue breast-feeding or to not administer ZINPLAVA, taking into account the importance of ZINPLAVA to the mother.

### Fertility

No clinical data are available on the possible effects of bezlotoxumab on fertility. Fertility studies have not been conducted in animals. There was no binding of bezlotoxumab to reproductive tissue in tissue cross-reactivity studies, and no notable effects in the male and female reproductive organs in repeat dose toxicity studies in mice (see section 5.3).

## 4.7 Effects on ability to drive and use machines

Bezlotoxumab has no or negligible influence on the ability to drive and use machines.

## 4.8 Undesirable effects

### Summary of the safety profile

The safety profile of ZINPLAVA was assessed in two Phase 3 clinical studies in adults. The most common adverse reactions following treatment with ZINPLAVA (reported in  $\geq 4\%$  of patients within the first 4 weeks of infusion) were nausea, diarrhoea, pyrexia and headache. These adverse reactions were reported at a similar frequency in placebo treated patients compared with ZINPLAVA-treated patients.

### Tabulated list of adverse reactions

Table 1 presents the adverse reactions reported within 4 weeks of infusion in ZINPLAVA-treated patients and listed by System Organ Class. The frequency of adverse reactions is defined as follows: very common ( $\geq 1/10$ ); common ( $\geq 1/100$  to  $< 1/10$ ); uncommon ( $\geq 1/1\,000$  to  $< 1/100$ ); rare ( $\geq 1/10\,000$  to  $< 1/1\,000$ ); very rare ( $< 1/10\,000$ ); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing frequency.

**Table 1: Adverse Reactions with ZINPLAVA**

MedDRA System Organ Class	Frequency	Adverse Reaction(s)
Nervous system disorders	Common	Headache
Gastrointestinal disorders	Common	Nausea, diarrhoea
General disorders and administration site conditions	Common	Pyrexia
Injury, poisoning and procedural complications	Common	Infusion related reactions†

† See Description of selected adverse reactions below.

## Description of selected adverse reactions

### *Serious adverse reactions*

In clinical studies, serious adverse reactions occurring within 12 weeks following infusion were reported in 29 % of ZINPLAVA-treated patients and 33 % in patients receiving placebo.

### *Infusion related reactions*

Overall, 10 % of subjects in the ZINPLAVA group experienced one or more infusion specific adverse reactions on the day of, or the day after, the infusion compared to 8 % in the placebo group. Infusion specific adverse reactions reported in  $\geq 0.5$  % of subjects receiving ZINPLAVA and at a frequency greater than placebo were nausea (3 %), fatigue (1 %), pyrexia (1 %), dizziness (1 %), headache (2 %), dyspnoea (1 %) and hypertension (1 %). Of the patients who experienced an infusion specific adverse reaction, the majority reported a reaction with a maximum intensity of mild (78 %) or moderate (20 %), and the majority of reactions resolved within 24 hours following onset.

### *Immune-related adverse reactions*

In a Phase 1 clinical trial, healthy subjects received two consecutive doses of 10 mg/kg of bezlotoxumab separated by 12 weeks. The adverse reactions after the second dose were not markedly different from those observed after the first dose, and are consistent with adverse reactions observed in the two Phase 3 trials (MODIFY I and MODIFY II; see section 5.1) in which all patients received a single dose.

## Paediatric population

The safety of ZINPLAVA was assessed in one Phase 3 clinical trial (MODIFY III) in which 107 paediatric patients 1 to < 18 years of age (4 patients 1 to < 2 years, 33 patients 2 to < 6 years, 26 patients 6 to < 12 years, and 44 patients 12 to < 18 years) received a single dose of 10 mg/kg of ZINPLAVA. The safety profile in paediatric patients was consistent with that in adults.

## Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via [the national reporting system listed in Appendix V](#).

## **4.9 Overdose**

There is no clinical experience with overdosage of ZINPLAVA. In clinical trials, healthy subjects received up to 20 mg/kg, which was generally well tolerated. In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment should be instituted.

# **5. PHARMACOLOGICAL PROPERTIES**

## **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Antiinfectives for systemic use, antibacterial monoclonal antibodies.  
ATC code: J06BC03

### Mechanism of action

Bezlotoxumab is a human monoclonal antitoxin antibody that binds with high affinity to *C. difficile* toxin B and neutralizes its activity. Bezlotoxumab prevents CDI recurrence by providing passive immunity against toxin produced by the outgrowth of persistent or newly-acquired *C. difficile* spores.

## Pharmacodynamic effects

### *Microbiology*

#### *Activity in vitro and in vivo*

The toxin B epitope to which bezlotoxumab binds is conserved, though not identical, across all known toxin sequences.

### Clinical trials

The efficacy of ZINPLAVA (bezlotoxumab) was investigated in two randomised, double-blind, placebo-controlled, multicentre, Phase 3 studies (MODIFY I and MODIFY II) where 810 patients were randomised to bezlotoxumab and 803 to placebo. The number of patients completing the studies and included in the full analysis set (FAS) was 781 in the ZINPLAVA group versus 773 in the placebo group. All patients received concomitant standard of care antibacterial therapy for CDI. Randomisation was stratified by the antibacterial agent and hospitalisation status (inpatient vs. outpatient) at the time of study entry. Adult patients had a confirmed diagnosis of CDI, which was defined as diarrhoea (passage of 3 or more loose bowel movements as defined in the Bristol stool chart as types 5 through 7 in 24 or fewer hours) and a positive stool test for toxigenic *C. difficile* from a stool sample collected no more than 7 days before study entry.

Patients received a 10- to 14-day course of oral antibacterial therapy for CDI (metronidazole, vancomycin or fidaxomicin, chosen by the investigator). Patients on oral vancomycin or oral fidaxomicin could have also received IV metronidazole.

A single infusion of ZINPLAVA or placebo was administered prior to completion of antibacterial therapy and patients were followed for 12 weeks following the infusion. The day of the infusion of ZINPLAVA or placebo ranged from prior to the start of antibacterial therapy up to day 14 of treatment, with a median on day 3.

The baseline characteristics of the 781 patients receiving ZINPLAVA and 773 receiving placebo were generally similar across treatment groups. The median age was 65 years, 85 % were white, 57 % were female, and 68 % were inpatients. A similar proportion of patients were receiving oral metronidazole (48 %) or oral vancomycin (48 %) and only 4 % were receiving fidaxomicin as antibacterial treatment for CDI.

The CDI recurrence rates are shown in Table 2.

**Table 2: CDI Recurrence Rate Through 12 Weeks After Infusion (MODIFY I and MODIFY II, Full Analysis Set\*)**

<b>ZINPLAVA with SoC<sup>†</sup></b> <b>Percent (n/N)</b>	<b>Placebo with SoC<sup>†</sup></b> <b>Percent (n/N)</b>	<b>Adjusted Difference (95% CI)<sup>‡</sup></b>	<b>p-value</b>
16.5 (129/781)	26.6 (206/773)	-10.0 (-14.0, -6.0)	<0.0001
<p>n = Number of patients in the analysis population meeting the criteria for endpoint N = Number of patients included in the analysis population * Full Analysis Set = a subset of all randomised patients with exclusions for: (i) did not receive infusion of study medication, (ii) did not have a positive local stool test for toxigenic <i>C. difficile</i>; (iii) did not receive protocol defined standard of care therapy within a 1-day window of the infusion; (iv) GCP non-compliance † SoC = Standard of Care antibacterial (metronidazole or vancomycin or fidaxomicin) ‡ One sided p-value based on the Miettinen and Nurminen method stratified by protocol (MODIFY I and MODIFY II), SoC antibacterial (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient)</p>			

Table 3 shows the results of a prospectively planned combined analysis of the CDI recurrence rates in pre-specified subgroups of patients at high risk for CDI recurrence across the two Phase 3 Trials. Overall, 51 % were ≥ 65 years, 29% were ≥ 75 years and 39 % received one or more systemic

antibacterial agents during the 12-week follow-up period. Of the total 28 % had one or more episodes of CDI within the six months prior to the episode under treatment (18 % of the patients had one, 7 % had two and a few patients had 3 or more prior episodes). Twenty-one (21) percent of the patients were immunocompromised and 16 % presented with clinically severe CDI. Among the 976/1554 (62 %) patients who had a positive baseline stool culture for *C. difficile* a hypervirulent strain (ribotypes 027, 078 or 244) was isolated in 22 % (217 of 976 patients), of which the majority (87 %, 189 of 217 strains) were ribotype 027.

These patients presented with risk factors primarily but not exclusively associated with higher risk of CDI recurrence. Efficacy results did not point towards a benefit of ZINPLAVA in patients with no known risk factors for CDI.

**Table 3: CDI Recurrence Rate by Risk Factor Subgroup  
(MODIFY I and MODIFY II, Full Analysis Set\*)**

Characteristic at study entry	ZINPLAVA with SoC <sup>†</sup> Percent (n/m)	Placebo with SoC <sup>†</sup> Percent (n/m)	Difference (95% CI) <sup>‡</sup>
Age ≥ 65 years	15.4 (60/390)	31.4 (127/405)	-16.0 (-21.7, -10.2)
History of one or more episodes of CDI in past 6 months	25.0 (54/216)	41.1 (90/219)	-16.1 (-24.7, -7.3)
Immunocompromised <sup>§</sup>	14.6 (26/178)	27.5 (42/153)	-12.8 (-21.7, -4.1)
Severe CDI <sup>¶</sup>	10.7 (13/122)	22.4 (28/125)	-11.7 (-21.1, -2.5)
Infected with a hypervirulent strain <sup>#</sup>	21.6 (22/102)	32.2 (37/115)	-10.6 (-22.1, 1.3)
Infected with 027 ribotype	23.6 (21/89)	34.0 (34/100)	-10.4 (-23.0, 2.6)
n = Number of patients within subgroup that met the criteria for endpoint m = Number of patients within subgroup * Full Analysis Set = a subset of all randomised patients with exclusions for: (i) did not receive infusion of study medication, (ii) did not have a positive local stool test for toxigenic <i>C. difficile</i> ; (iii) did not receive protocol defined standard of care therapy within a 1-day window of the infusion † SoC = Standard of Care antibacterial (metronidazole or vancomycin or fidaxomicin) ‡ Based on the Miettinen and Nurminen method without stratification § Based on medical conditions or medications received that may result in immunosuppression ¶ Zar score ≥ 2 # Hypervirulent strain included the following: 027, 078, or 244 ribotypes			

In the studies, the clinical cure rates of the presenting CDI episode were comparable between the treatment arms.

### Paediatric population

ZINPLAVA was evaluated in a randomised, double-blind, placebo-controlled, multi-centre trial (MODIFY III) in paediatric patients aged 1 to < 18 years. Enrolled patients had a diagnosis of CDI and received SoC (vancomycin, metronidazole, or fidaxomicin) for the baseline CDI episode. In this trial, 143 patients were randomised and treated, of whom 107 received a single infusion of ZINPLAVA (10 mg/kg) and 36 received a placebo infusion. Of these randomised patients, 58% were 1 to < 12 years of age, 52% were male, 80% were white, and 7% were multi-racial. The majority (94%) of patients had one or more risk factors for CDI recurrence. The most common risk factors were being immunocompromised (72.7%) and having received treatment with 1 or more systemic antibacterial agents during treatment for CDI during the baseline episode (62.6%).

The primary objectives in this study were to assess safety and pharmacokinetics of bezlotoxumab; efficacy was a secondary descriptive endpoint. For results concerning pharmacokinetics, please refer to section 5.2. Following administration of a single infusion of bezlotoxumab or placebo, the percentage of patients in the mITT population with initial clinical response who had CDI recurrence within 12 weeks and were at high risk for CDI recurrence was 12.1% (11/91) vs. 15.2% (5/33), respectively.

## Immunogenicity

Immunogenicity of ZINPLAVA was evaluated using electrochemiluminescence (ECL) assays in MODIFY I, MODIFY II and MODIFY III.

Following treatment with ZINPLAVA in MODIFY I and MODIFY II, none of the 710 evaluable patients tested positive for treatment-emergent anti-bezlotoxumab antibodies. Although ZINPLAVA is intended for single dose administration, the immunogenicity of bezlotoxumab following a second administration of 10 mg/kg, 12 weeks after the first dose, was assessed in 29 healthy subjects. No anti-bezlotoxumab antibodies were detected after the second dose.

Following treatment with ZINPLAVA in MODIFY III, 2 of the 100 evaluable paediatric patients tested positive for anti-bezlotoxumab antibodies; neither had neutralizing antibodies.

There are no data on repeated administration of bezlotoxumab in patients with CDI.

## **5.2 Pharmacokinetic properties**

### Absorption

Bezlotoxumab is dosed via the IV route and therefore is immediately and completely bioavailable. After a single IV dose of 10 mg/kg bezlotoxumab, geometric mean (%CV)  $AUC_{(0-\infty)}$ ,  $C_{max}$ , and  $C_{12\text{ weeks}}$  were 53 000 mcg.h/mL (40.2%), 185 mcg/mL (20.7%), and 3.23 mcg/mL (120.7%), respectively, in patients with CDI. Bezlotoxumab exposures in healthy subjects increased in an approximately dose proportional manner across the 0.3 to 20 mg/kg dose range.

### Distribution

Bezlotoxumab has limited extravascular distribution. The mean volume of distribution of bezlotoxumab was 7.33 L (CV: 16 %).

### Biotransformation

Bezlotoxumab is catabolized through protein degradation processes; metabolism does not contribute to its clearance.

### Elimination

Bezlotoxumab is eliminated from the body primarily by protein degradation. The mean clearance of bezlotoxumab was 0.317 L/day (CV: 41 %) and the terminal half-life ( $t_{1/2}$ ) was approximately 19 days (28 %).

### Special populations

The effects of various covariates on the pharmacokinetics of bezlotoxumab were assessed in a population pharmacokinetic analysis. The clearance of bezlotoxumab increased with increasing body weight; the resulting exposure differences are adequately addressed by the administration of a weight-based dose.

The following factors had no clinically meaningful effect on the exposure of bezlotoxumab and no dose adjustment is required: age (range 18 to 100 years), gender, race, ethnicity, renal impairment, hepatic impairment, and presence of co-morbid conditions.



### *Renal impairment*

The effect of renal impairment on the pharmacokinetics of bezlotoxumab was evaluated in patients with mild (eGFR 60 to < 90 mL/min/1.73 m<sup>2</sup>), moderate (eGFR 30 to < 60 mL/min/1.73 m<sup>2</sup>), or severe (eGFR 15 to < 30 mL/min/1.73 m<sup>2</sup>) renal impairment, or with end stage renal disease (eGFR < 15 mL/min/1.73 m<sup>2</sup>), as compared to patients demonstrating normal (eGFR ≥ 90 mL/min/1.73 m<sup>2</sup>) renal function. No clinically meaningful differences in the exposure of bezlotoxumab were found between patients with renal impairment and patients with normal renal function.

### *Hepatic impairment*

The effect of hepatic impairment on the pharmacokinetics of bezlotoxumab was evaluated in patients with hepatic impairment (defined as having two or more of the following: [1] albumin ≤ 3.1 g/dL; [2] ALT ≥ 2 X ULN; [3] total bilirubin ≥ 1.3 X ULN; or [4] mild, moderate or severe liver disease as reported by the Charlson Co-morbidity Index), as compared to patients with normal hepatic function. No clinically meaningful differences in the exposure of bezlotoxumab were found between patients with hepatic impairment and patients with normal hepatic function.

### *Elderly*

The effect of age on the pharmacokinetics of bezlotoxumab was evaluated in patients ranging from 18 to 100 years of age. No clinically meaningful differences in the exposure of bezlotoxumab were found between elderly patients 65 years and older and patients under 65 years of age.

### *Paediatric population*

The pharmacokinetics of bezlotoxumab in paediatric patients 1 year of age and older (N=91) who were administered a single intravenous infusion of 10 mg/kg bezlotoxumab are shown in Table 4. Bezlotoxumab exposure (AUC<sub>0-inf</sub>) in paediatric patients was similar to that in adults.

**Table 4: Summary of Bezlotoxumab Pharmacokinetics Following the Administration of a Single Infusion of 10 mg/kg Bezlotoxumab by Age Group in Paediatric Patients**

	Age Group			
	1 to < 4 years (N=20)	4 to < 7 years (N=13)	7 to < 12 years (N=21)	12 to < 18 years (N=37)
PK Parameter	Geometric Mean (%CV)			
C <sub>max</sub> (mcg/mL)	112 (37.4%)	136 (32.2%)	143 (24.0%)	155 (28.2%)
AUC <sub>inf</sub> (mcg*h/mL)	44 500 (33.4%)	40 400 (33.7%)	43 600 (38.5%)	56 100 (30.7%) <sup>†</sup>
C <sub>12 weeks</sub> (mcg/mL)	2.70 (83.2%) <sup>‡</sup>	1.46 (196.6%)	2.45 (88.7%) <sup>‡</sup>	3.85 (73.0%) <sup>†</sup>
Terminal Half-Life (days)	18.4 (32.0%)	17.6 (36.6%)	18.2 (35.3%)	21.7 (22.1%) <sup>†</sup>
Clearance (L/day)	0.070 (33.2%)	0.116 (44.2%)	0.171 (45.0%)	0.240 (33.7%) <sup>†</sup>
Volume of Distribution (L)	1.85 (39.1%)	2.95 (36.8%)	4.51 (27.7%)	7.50 (33.3%) <sup>†</sup>

<sup>†</sup>- N=36; PK parameters except C<sub>max</sub> could not be determined in one subject due to incomplete concentration-time profile

<sup>‡</sup>- N=19; C<sub>12 weeks</sub> not determined for 1 or 2 subjects

**Table 5: Summary of Bezlotoxumab Pharmacokinetics Following the Administration of a Single Infusion of 10 mg/kg Bezlotoxumab by Body Weight in Paediatric Patients**

	Body Weight Group				
	<15 kg (N=14)	15 to <20 kg (N=13)	20 to <30 kg (N=17)	30 to <40 kg (N=13)	≥40 kg (N=34)
PK Parameter	Geometric Mean (%CV)				
C <sub>max</sub> (mcg/mL)	123 (31.5%)	116 (49.4%)	130 (20.4%)	144 (25.8%)	160 (26.4%)
AUC <sub>inf</sub> (mcg*h/mL)	43 400 (35.3%)	44 400 (32.5%)	39 000 (41.1%)	44 800 (25.4%)	58 900 (28.0%) <sup>†</sup>
C <sub>12 weeks</sub> (mcg/mL)	2.32 (67.8%) <sup>‡</sup>	2.81 (92.9%)	1.84 (199.5%) <sup>§</sup>	2.49 (80.0%)	3.79 (82.6%) <sup>†</sup>
Terminal Half- Life (days)	17.3 (29.7%)	20.3 (26.2%)	17.7 (46.5%)	20.2 (23.4%)	20.9 (24.4%) <sup>†</sup>
Clearance (L/day)	0.063 (29.5%)	0.093 (32.0%)	0.146 (47.0%)	0.191 (23.8%)	0.250 (35.0%) <sup>†</sup>
Volume of Distribution (L)	1.57 (31.4%)	2.72 (33.3%)	3.72 (31.2%)	5.56 (21.8%)	7.51 (35.2%) <sup>†</sup>

<sup>†</sup> N=33; PK parameters except C<sub>max</sub> could not be determined in one subject due to incomplete concentration-time profile

<sup>‡</sup> N=13; C<sub>12 weeks</sub> not determined for 1 subject

<sup>§</sup> N=15; C<sub>12 weeks</sub> not determined for 2 subject

There is no apparent relationship between bezlotoxumab exposure and body weight following weight-based dosing of bezlotoxumab in paediatric patients. Based on population pharmacokinetic analysis of bezlotoxumab, the following factors had no clinically meaningful effect on the exposure of bezlotoxumab: age, sex, renal impairment, and race.

### **5.3 Preclinical safety data**

Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity. Genotoxicity and carcinogenic potential have not been evaluated.

Animal reproduction or developmental toxicity studies have not been conducted with bezlotoxumab. There were no notable effects in the male and female reproductive organs in mice based on repeat dose toxicity studies and no binding to reproductive tissues was observed in tissue cross-reactivity studies.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Citric acid monohydrate (E330)  
Diethylenetriaminepentaacetic acid  
Polysorbate 80 (E433)  
Sodium chloride  
Sodium citrate dihydrate (E331)  
Water for injections  
Sodium hydroxide (E524) (for pH adjustment).

### **6.2 Incompatibilities**

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

### **6.3 Shelf life**

Unopened vial: 3 years.

Solution for infusion: Chemical and physical in-use stability has been demonstrated for 24 hours at 2°C – 8°C or 16 hours at room temperature (at or below 25°C). These time limits include storage of the infusion solution in the IV bag through the duration of infusion. From a microbiological point of view, the product must be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and must not be longer than a total of 24 hours at 2°C – 8°C or 16 hours at room temperature (at or below 25°C).

### **6.4 Special precautions for storage**

Store in a refrigerator 2 °C to 8 °C. Do not freeze. Keep vial in the outer carton in order to protect from light.

For storage conditions after dilution of the medicinal product, see section 6.3.

### **6.5 Nature and contents of container**

Type I glass vial containing 40 mL or 25 mL solution, with a chlorobutyl stopper, and a flip-off cap seal.

Each carton contains one vial.

## **6.6 Special precautions for disposal and other handling**

### Preparation of diluted solution

- Prepare the diluted solution immediately after removal of the vial(s) from refrigerated storage, or the vial(s) may be stored at room temperature protected from light for up to 24 hours prior to preparation of the diluted solution.
- Inspect vial contents for discoloration and particulate matter prior to dilution. ZINPLAVA is a clear to moderately opalescent, colourless to pale yellow liquid. Do not use the vial if the solution is discoloured or contains visible particles.
- Do not shake the vial.
- Withdraw the required volume from the vial(s) based on the patient's weight (in kg) and transfer into an IV bag containing either 0.9 % Sodium Chloride Injection, or 5 % Dextrose Injection, to prepare a diluted solution with a final concentration ranging from 1 to 10 mg/mL. Mix diluted solution by gentle inversion.
- Discard vial(s) and all unused contents.
- If the diluted solution is refrigerated, allow the IV bag to come to room temperature prior to use.
- Do not freeze the diluted solution.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.  
Waarderweg 39  
2031 BN Haarlem  
The Netherlands

## **8. MARKETING AUTHORISATION NUMBER(S)**

EU/1/16/1156/001  
EU/1/16/1156/002

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 18 January 2017  
Date of latest renewal: 01 September 2021

## **10. DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu>.

## **ANNEX II**

- A. MANUFACTURER OF THE BIOLOGICAL ACTIVE  
SUBSTANCE AND MANUFACTURER(S) RESPONSIBLE  
FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY  
AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE  
MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO  
THE SAFE AND EFFECTIVE USE OF THE MEDICINAL  
PRODUCT**

**A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer of the biological active substance

Lonza Biologics Inc.  
101 International Drive  
Portsmouth  
New Hampshire  
03801  
United States

Name and address of the manufacturer(s) responsible for batch release

Organon Heist bv  
Industriepark 30  
2220 Heist-op-den-Berg  
Belgium

Merck Sharp & Dohme B.V.  
Waarderweg 39  
2031 BN Haarlem  
The Netherlands

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Medicinal product subject to medical prescription.

**C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

- **Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

**D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

- **Risk management plan (RMP)**

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being

reached.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**



## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING****OUTER CARTON****1. NAME OF THE MEDICINAL PRODUCT**

ZINPLAVA 25 mg/mL concentrate for solution for infusion  
bezlotoxumab

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each 40 mL vial contains 1 000 mg bezlotoxumab.  
Each mL contains 25 mg bezlotoxumab.

**3. LIST OF EXCIPIENTS**

Excipients: Citric acid monohydrate, diethylenetriaminepentaacetic acid, polysorbate 80, sodium chloride, sodium citrate dihydrate, water for injections, sodium hydroxide.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Concentrate for solution for infusion

1 vial

1 000 mg/40 mL

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.  
Intravenous use after dilution  
Single dose vial

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY****8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

**Store in a refrigerator. Do not freeze.** Keep the vial in the outer carton in order to protect from light.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.  
Waarderweg 39  
2031 BN Haarlem  
The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/16/1156/001

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Justification for not including Braille accepted.

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC  
SN  
NN

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING  
VIAL LABEL**

**1. NAME OF THE MEDICINAL PRODUCT**

ZINPLAVA 25 mg/mL concentrate for solution for infusion  
bezlotoxumab

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each vial contains 1 000 mg bezlotoxumab.  
Each mL contains 25 mg bezlotoxumab.

**3. LIST OF EXCIPIENTS**

Excipients: Citric acid monohydrate, diethylenetriaminepentaacetic acid, polysorbate 80, sodium chloride, sodium citrate dihydrate, water for injections, sodium hydroxide.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Concentrate for solution for infusion  
1 vial  
1 000 mg/40 mL

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.  
Intravenous use after dilution  
Single dose vial

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT  
OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

**Store in a refrigerator. Do not freeze.** Keep the vial in the outer carton in order to protect from light.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

MSD

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/16/1156/001

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

**17. UNIQUE IDENTIFIER – 2D BARCODE**

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING****OUTER CARTON****1. NAME OF THE MEDICINAL PRODUCT**

ZINPLAVA 25 mg/mL concentrate for solution for infusion  
bezlotoxumab

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each 25 mL vial contains 625 mg bezlotoxumab.  
Each mL contains 25 mg bezlotoxumab.

**3. LIST OF EXCIPIENTS**

Excipients: Citric acid monohydrate, diethylenetriaminepentaacetic acid, polysorbate 80, sodium chloride, sodium citrate dihydrate, water for injections, sodium hydroxide.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Concentrate for solution for infusion

1 vial

625 mg/25 mL

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.  
Intravenous use after dilution  
Single dose vial

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY****8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

**Store in a refrigerator. Do not freeze.** Keep the vial in the outer carton in order to protect from light.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Merck Sharp & Dohme B.V.  
Waarderweg 39  
2031 BN Haarlem  
The Netherlands

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/16/1156/002

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Justification for not including Braille accepted.

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC  
SN  
NN

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING  
VIAL LABEL**

**1. NAME OF THE MEDICINAL PRODUCT**

ZINPLAVA 25 mg/mL concentrate for solution for infusion  
bezlotoxumab

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

Each vial contains 625 mg bezlotoxumab.  
Each mL contains 25 mg bezlotoxumab.

**3. LIST OF EXCIPIENTS**

Excipients: Citric acid monohydrate, diethylenetriaminepentaacetic acid, polysorbate 80, sodium chloride, sodium citrate dihydrate, water for injections, sodium hydroxide.

**4. PHARMACEUTICAL FORM AND CONTENTS**

Concentrate for solution for infusion  
1 vial  
625 mg/25 mL

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.  
Intravenous use after dilution  
Single dose vial

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT  
OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP



**9. SPECIAL STORAGE CONDITIONS**

**Store in a refrigerator. Do not freeze.** Keep the vial in the outer carton in order to protect from light.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

MSD

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/16/1156/002

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

**17. UNIQUE IDENTIFIER – 2D BARCODE**

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

## **B. PACKAGE LEAFLET**

## **Package leaflet: Information for the patient**

### **ZINPLAVA 25 mg/mL concentrate for solution for infusion** bezlotoxumab

**Read all of this leaflet carefully before you are given this medicine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor.
- If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

#### **What is in this leaflet**

1. What ZINPLAVA is and what it is used for
2. What you need to know before you are given ZINPLAVA
3. How you are given ZINPLAVA
4. Possible side effects
5. How to store ZINPLAVA
6. Contents of the pack and other information

#### **1. What ZINPLAVA is and what it is used for**

ZINPLAVA contains the active substance bezlotoxumab.

ZINPLAVA is a medicine that is given together with an antibiotic to prevent *Clostridioides difficile* infection (CDI) from coming back in adults and children 1 year of age or older who have a high risk of CDI coming back.

#### **How ZINPLAVA works**

- When people get CDI, they are usually given an antibiotic to get rid of the infection, but CDI can often come back within weeks or months.
- The bacteria responsible for CDI produce a toxin that can inflame and damage your colon, causing stomach pain and severe diarrhoea. ZINPLAVA acts by attaching to the toxin and blocking it, thereby preventing the symptoms of CDI from coming back.

#### **2. What you need to know before you are given ZINPLAVA**

Talk to your doctor before you are given ZINPLAVA.

#### **You should not be given ZINPLAVA if:**

- you are allergic to bezlotoxumab or any of the other ingredients of this medicine (listed in section 6).

#### **Warnings and precautions**

ZINPLAVA is not a treatment for CDI. ZINPLAVA has no effect on the CDI you have now.

ZINPLAVA is given with the antibiotic therapy you are taking for CDI.

#### **Children**

ZINPLAVA should not be used in children below 1 year of age.

#### **Other medicines and ZINPLAVA**

Tell your doctor if you are taking, have recently taken or might take any other medicines.

### **Pregnancy and breast-feeding**

- If you are pregnant or trying to get pregnant, tell your doctor.
- We don't know if ZINPLAVA will harm your baby while you are pregnant.
- If you are breast-feeding or are planning to breast-feed, check with your doctor first.
- We don't know if ZINPLAVA gets in your breast milk and is passed to your baby.
- You and your doctor should decide together if you will use ZINPLAVA.

### **Driving and using machines**

ZINPLAVA has no or very little effect on the ability to drive and use machines.

### **ZINPLAVA contains sodium**

This medicine contains up to 182.8 mg sodium (main component of cooking / table salt) in each vial. This is equivalent to 9.1 % of the recommended maximum daily dietary intake of sodium for an adult.

### **3. How you are given ZINPLAVA**

- You will get ZINPLAVA as an infusion (drip) into a vein.
- You will get ZINPLAVA in one dose and it will take about 1 hour. Your dose will be calculated using your body weight.
- You should keep taking your antibiotic for CDI as directed by your doctor.

### **If you miss an appointment to get ZINPLAVA**

- Call your doctor or healthcare professional right away to reschedule your appointment.
- It is very important that you do not miss the dose of this medicine.

If you have any further questions on the use of this medicine, ask your doctor.

### **4. Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects have been reported in clinical trials:

#### **Common** (may affect up to 1 in 10 people)

- diarrhoea
- dizziness
- feeling sick (nausea)
- fever
- headache
- high blood pressure
- shortness of breath
- tiredness

Tell your doctor or health care professional if you notice any of the side effects above.

### **Reporting of side effects**

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly **the national reporting system** listed in [Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

## 5. How to store ZINPLAVA

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator 2 °C to 8 °C. Do not freeze. Keep vial in the outer carton in order to protect from light.

The diluted solution of ZINPLAVA may be stored either at room temperature for up to 16 hours or under refrigeration at 2 °C to 8 °C for up to 24 hours. If refrigerated, allow the IV bag to come to room temperature prior to use.

Do not store any unused portion of the infusion solution for reuse. Any unused medicine or waste material should be disposed of in accordance with local requirements.

## 6. Contents of the pack and other information

### What ZINPLAVA contains

- The active substance is bezlotoxumab. Each mL of concentrate contains 25 mg of bezlotoxumab.  
One 40 mL vial contains 1 000 mg of bezlotoxumab.  
One 25 mL vial contains 625 mg of bezlotoxumab.
- The other ingredients are citric acid monohydrate (E330), diethylenetriaminepentaacetic acid, polysorbate 80 (E433), sodium chloride, sodium citrate dihydrate (E331), water for injections, and sodium hydroxide (E524) (for pH adjustment).

### What ZINPLAVA looks like and contents of the pack

The concentrate for solution for infusion is a clear to moderately opalescent, colourless to pale yellow liquid.

It is available in cartons containing one glass vial.

### Marketing Authorisation Holder

Merck Sharp & Dohme B.V.  
Waarderweg 39  
2031 BN Haarlem  
The Netherlands

### Manufacturer

Organon Heist bv  
Industriepark 30  
2220 Heist-op-den-Berg  
Belgium

Merck Sharp & Dohme B.V.  
Waarderweg 39  
2031 BN Haarlem  
The Netherlands

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**België/Belgique/Belgien**

MSD Belgium  
Tél/Tel: +32(0)27766211  
dpoc\_belux@msd.com

**Lietuva**

UAB Merck Sharp & Dohme  
Tel. + 370 5 278 02 47  
msd\_lietuva@merck.com

**България**

Мерк Шарп и Доум България ЕООД  
Тел.: +359 2 819 3737  
info-msdbg@merck.com

**Luxembourg/Luxemburg**

MSD Belgium  
Tél/Tel: +32(0)27766211  
dpoc\_belux@msd.com

**Česká republika**

Merck Sharp & Dohme s.r.o.  
Tel: +420 233 010 111  
dpoc\_czechslovak@merck.com

**Magyarország**

MSD Pharma Hungary Kft.  
Tel.: +36 1 888 5300  
hungary\_msd@merck.com

**Danmark**

MSD Danmark ApS  
Tlf: + 45 4482 4000  
dkmail@merck.com

**Malta**

Merck Sharp & Dohme Cyprus Limited  
Tel: 8007 4433 (+356 99917558)  
malta\_info@merck.com

**Deutschland**

MSD Sharp & Dohme GmbH  
Tel: 0800 673 673 673 (+49 (0) 89 4561 0)  
e-mail@msd.de

**Nederland**

Merck Sharp & Dohme B.V.  
Tel: 0800 9999000  
(+31 23 5153153)  
medicalinfo.nl@merck.com

**Eesti**

Merck Sharp & Dohme OÜ  
Tel.: +372 6144 200  
msdeesti@merck.com

**Norge**

MSD (Norge) AS  
Tlf: +47 32 20 73 00  
msdnorge@msd.no

**Ελλάδα**

MSD A.Φ.B.E.E.  
Τηλ: +30 210 98 97 300  
dpoc\_greece@merck.com

**Österreich**

Merck Sharp & Dohme Ges.m.b.H.  
Tel: +43 (0) 1 26 044  
dpoc\_austria@merck.com

**España**

Merck Sharp & Dohme de España, S.A.  
Tel: +34 91 321 06 00  
msd\_info@merck.com

**Polska**

MSD Polska Sp. z o.o.  
Tel: +48 22 549 51 00  
msdpolska@merck.com

**France**

MSD France  
Tél: + 33 (0) 1 80 46 40 40

**Portugal**

Merck Sharp & Dohme, Lda  
Tel: +351 21 4465700  
inform\_pt@merck.com

**Hrvatska**

Merck Sharp & Dohme d.o.o.  
Tel: + 385 1 6611 333  
croatia\_info@merck.com

**România**

Merck Sharp & Dohme Romania S.R.L.  
Tel: +40 21 529 29 00  
msdromania@merck.com

**Ireland**

Merck Sharp & Dohme Ireland (Human Health)  
Limited  
Tel: +353 (0)1 2998700  
medinfo\_ireland@msd.com

**Ísland**

Vistor hf.  
Sími: + 354 535 7000

**Italia**

MSD Italia S.r.l.  
Tel: 800 23 99 89 (+39 06 361911)  
medicalinformation.it@msd.com

**Κύπρος**

Merck Sharp & Dohme Cyprus Limited  
Τηλ.: 800 00 673 (+357 22866700)  
cyprus\_info@merck.com

**Latvija**

SIA Merck Sharp & Dohme Latvija  
Tel: + 371 67364224  
msd\_lv@merck.com

**Slovenija**

Merck Sharp & Dohme, inovativna zdravila d.o.o.  
Tel: +386 1 5204 201  
msd.slovenia@merck.com

**Slovenská republika**

Merck Sharp & Dohme, s. r. o.  
Tel: +421 2 58282010  
dpoc\_czechslovak@merck.com

**Suomi/Finland**

MSD Finland Oy  
Puh/Tel: +358 (0)9 804 650  
info@msd.fi

**Sverige**

Merck Sharp & Dohme (Sweden) AB  
Tel: +46 77 5700488  
medicinskinfo@merck.com

**United Kingdom (Northern Ireland)**

Merck Sharp & Dohme Ireland (Human Health)  
Limited  
Tel: +353 (0)1 2998700  
medinfoNI@msd.com

**This leaflet was last revised in {month YYYY}.**

**Other sources of information**

Detailed information on this medicine is available on the European Medicines Agency web site:  
<http://www.ema.europa.eu>.

**The following information is intended for healthcare professionals only:**Preparation of diluted solution

- Prepare the diluted solution immediately after removal of the vial(s) from refrigerated storage, or the vial(s) may be stored at room temperature protected from light for up to 24 hours prior to preparation of the diluted solution.
- Inspect vial contents for discoloration and particulate matter prior to dilution. ZINPLAVA is a clear to moderately opalescent, colourless to pale yellow liquid. Do not use the vial if the solution is discoloured or contains visible particles.
- Do not shake the vial.
- Withdraw the required volume from the vial(s) based on the patient's weight (in kg) and transfer into an IV bag containing either 0.9 % Sodium Chloride Injection, or 5 % Dextrose Injection, to prepare a diluted solution with a final concentration ranging from 1 to 10 mg/mL. Mix diluted solution by gentle inversion.
- Discard vial(s) and all unused contents.
- If the diluted solution is refrigerated, allow the IV bag to come to room temperature prior to use.
- Do not freeze the diluted solution.

#### Method of administration

- Administer the diluted solution for infusion intravenously over 60 minutes using a sterile, non-pyrogenic, low-protein binding 0.2 micron to 5 micron in-line or add-on filter. ZINPLAVA should not be administered as an intravenous push or bolus.
- The diluted solution can be infused via a central line or peripheral catheter.
- ZINPLAVA must not be co-administered with other medicinal products simultaneously through the same infusion line.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.